Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-024876
Filing Date
2020-04-17
Accepted
2020-04-17 17:16:10
Documents
1
Period of Report
2020-03-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5058
  Complete submission text file 0001209191-20-024876.txt   6417
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 31 UPPER MOUNTAIN AVENUE APARTMENT 2 MONTCLAIR NJ 07042
Business Address
Cearnal Martin E (Reporting) CIK: 0001408500 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 20800526